10-K · March 10, 2026
LifeMD’s 2025 10-K emphasizes a vertically integrated, subscription-driven telehealth and pharmacy platform with scale initiatives (wholly-owned pharmacy, AI-enabled systems) and continued patient growth. The filing…
Earnings analysis · 10-Q
LFMD earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
LifeMD reported Q1 2026 revenue of $50.2 million, a slight decline of 1% from $50.9 million in Q1 2025, but exceeding estimates by 2.9%. The firm reported a wider EPS loss of $0.20 compared to the expected loss of…
Read full summary
LifeMD reported Q1 2026 revenue of $50.2 million, a slight decline of 1% from $50.9 million in Q1 2025, but exceeding estimates by 2.9%. The firm reported a wider EPS loss of $0.20 compared to the expected loss of $0.13, contributing to a negative sentiment around earnings despite improvements in gross margins and subscriber growth.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.2
- Gross margin
- 88.2%
What stood out
-
Q1 Revenue Exceeds Estimates
Actual revenue was $50.2 million, surpassing estimates of $48.8 million by 2.9%.
-
Improved Gross Margins
Gross profit margin increased to 88.2% in Q1 2026 from 84.0% in Q1 2025.
-
Significant Subscriber Growth
LifeMD served over 365,000 active patient subscribers as of March 31, 2026.
-
Cash Reserves of $34.5 Million
Cash position remained robust, providing a buffer for operational needs.
-
Operating Expenses Increased
Total expenses surged by 21% to approximately $53.2 million, driven by higher marketing costs.
-
Cash Flow From Operations
Net cash provided by operating activities was approximately $445K, down from $3.1 million in the prior year.
What to watch
-
Widening EPS Loss
Q1 2026 EPS was a loss of $0.20, compared to a loss of $0.06 in Q1 2025.
-
Increased Operating Expenses
Operating expenses rose 21% year-over-year, outpacing revenue growth.
-
Liquidity Concerns
Working capital decreased by $8.15 million to $2.1 million as cash decreased by $2.3 million.
Management's outlook
Management reaffirmed full-year 2026 revenue guidance of $220M to $230M.
Earlier filings 4
10-Q · November 17, 2025
LifeMD reported Q3 revenue of $60,172,470, up $6,900,176 (+12.95%) versus Q3 2024 but down modestly versus Q2 2025. Gross margin compressed to 87.7% (from 90.6% a year ago) while operating loss narrowed to $(1,969,214)…
10-Q · August 5, 2025
LifeMD reported Q2 revenue of $62,218,185 (up from $50,661,845 in Q2 2024) and a diluted loss per share of $(0.06). Gross profit improved to $54,787,281 and operating loss narrowed to $(906,772). The company generated…
10-Q · May 6, 2025
LifeMD reported strong top-line growth for the quarter: total revenue of $65,697,756 (up from $44,144,264 a year ago) and gross profit of $57,054,040. Operating income flipped to positive $2,542,924 (vs. an operating…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.